ABPI comment on NIHR framework for restarting paused research

The NIHR has set out a framework for resuming health research that was paused as a result of the COVID-19 pandemic. 

In response to today's announcement, Dr Sheuli Porkess, ABPI's Executive Director of Research, Medical and Innovation said: 

“This framework is a key first step in restarting clinical trials that have been paused due to COVID-19. It’s critical that vital scientific research can continue so that new treatments can be developed for patients.

“The health of patients must be our priority. The pharmaceutical industry will continue to work in partnership with the NHS and the Government to get the UK’s research ecosystem back up and running.”